From Financial Modeling Prep: 2024-11-18 12:21:00

Piper Sandler analysts lowered Moderna’s price target to $69 but maintained an Overweight rating, citing short-term challenges and long-term growth potential. Moderna shares hit a 52-week low due to various factors, including vaccination rate declines and uncertainty around leadership. Management expects product sales to rebound by 2025, driven by new vaccine launches.

Despite current challenges, Moderna remains optimistic about its innovative pipeline and long-term prospects. Piper Sandler views the current valuation as attractive for long-term investors, supporting the Overweight rating despite the reduced price target.



Read more at Financial Modeling Prep:: Piper Sandler Lowers Moderna Price Target Amid Cha…